{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:17:27Z","timestamp":1777918647540,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with high-grade serous ovarian carcinoma (HGSOC) often have a personal and\/or family history of breast cancers. However, the clinical association and underlying molecular interaction between breast cancer and HGSOC is not well understood. In this study, the clinical characteristics and outcomes of HGSOC patients with or without breast cancer were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eligible patient information was extracted from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier and Cox proportional hazards regression models were used to determine survival outcomes and prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 3065 HGSOC (ICD-O-3 code 8461\/3) patients were identified from 1975 to 2020, among whom 239 (9.56%) had co-existing breast cancers. HGSOC with breast cancers tended to have more stage I-II ovarian cancer (20.92% vs 13.79%), less metastatic diseases (25.1% vs 32.13%) and had a higher probability of undergoing surgery (94.1% vs 87.9%). The overall survival of HGSOC patients with breast cancer was better than that of patients without breast cancer (HR = 0.77, 95% CI 0.65 to 0.91;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0015). Further, patients who developed ovarian cancer before breast cancer had better overall survival than those who developed breast cancer before or simultaneously with ovarian cancer (HR = 0.35, 95% CI 0.23 to 0.52;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HGSOC combined with breast cancer is a common phenomenon. HGSOC patients with breast cancer, especially those diagnosed with ovarian cancer before breast cancer have a better prognosis. Further validation is warranted and more genetic and mechanistical study is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916251323224","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T01:42:56Z","timestamp":1741830176000},"page":"164-173","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of breast cancer in ovarian cancer patients and its impact on patient survival: An analysis of the surveillance, epidemiology, and end results data"],"prefix":"10.1177","volume":"111","author":[{"given":"Ni","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanfang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taikang Tongji (Wuhan) Hospital, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-3108","authenticated-orcid":false,"given":"Qiuji","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China"},{"name":"Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2"},{"key":"e_1_3_2_3_2","unstructured":"National Cancer Institute. (2024). SEER Ovarian Cancer https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html (accessed 13 January 2024)."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.02.001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040952"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4019"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02960"},{"key":"e_1_3_2_10_2","first-page":"50","article-title":"How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology","volume":"10","author":"Che WQ","year":"2023","unstructured":"Che WQ, Li YJ, Tsang CK, et al. How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology. Mil Med Res 2023; 10: 50.","journal-title":"Mil Med Res"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104081"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21754"},{"key":"e_1_3_2_13_2","article-title":"Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer","volume":"3","author":"Li Y","year":"2020","unstructured":"Li Y, Yang D, Yin X, et al. Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer. JAMA Netw Open 2020; 3: e1918160.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0427-5"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.009"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01148-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.07.101"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8545"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1703"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70214-5"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.8848"},{"key":"e_1_3_2_24_2","article-title":"Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients","author":"Wang X","year":"2023","unstructured":"Wang X, Zeng M, Ju X, et al. Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients. Br J Surg 2023; 111(1): znad377.","journal-title":"Br J Surg"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112"},{"key":"e_1_3_2_26_2","first-page":"631","article-title":"Multiple primary cancers in women with gynaecological malignancies: a cancer registry-based study in Umbria region of Italy","volume":"35","author":"Petrucci MS","year":"2014","unstructured":"Petrucci MS, Bianconi F, Dolciami F, et al. Multiple primary cancers in women with gynaecological malignancies: a cancer registry-based study in Umbria region of Italy. Eur J Gynaecol Oncol 2014; 35: 631-634.","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_3_2_27_2","article-title":"Association of BRCA1\/2 mutations with ovarian cancer prognosis: An updated meta-analysis","volume":"97","author":"Huang YW.","year":"2018","unstructured":"Huang YW. Association of BRCA1\/2 mutations with ovarian cancer prognosis: An updated meta-analysis. Medicine (Baltimore) 2018; 97: e9380.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs494"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.20"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2497"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05545-9"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32335"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00503-z"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.648"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9816"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.02.022"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5003"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6489"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251323224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916251323224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916251323224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:43:39Z","timestamp":1777661019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916251323224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/03008916251323224"],"URL":"https:\/\/doi.org\/10.1177\/03008916251323224","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}